{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-telemedicine-visits-and-remote-ae-reporting”
},
“headline”: “SOP for Telemedicine Visits and Remote AE Reporting”,
“description”: “This SOP describes standardized procedures for conducting telemedicine visits and remote adverse event (AE) reporting in clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements while protecting subject privacy and data integrity.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Telemedicine Visits and Remote AE Reporting

Purpose

The purpose of this SOP is to define standardized procedures for implementing telemedicine visits and remote adverse event (AE) reporting in clinical trials. It enables subject safety, data integrity, and regulatory compliance while facilitating decentralized and hybrid trial designs.

Scope

This SOP applies to sponsors, investigators, site staff, CROs, and regulatory teams involved in clinical trials using telemedicine and remote AE reporting solutions. It covers teleconsultation procedures, remote AE identification, documentation, reporting, privacy safeguards, and inspection readiness.

Responsibilities

• Sponsor: Ensures validated telemedicine platforms and oversees remote AE reporting compliance.
• Investigator: Conducts teleconsultations, assesses AEs, and ensures accurate documentation.
• Site Staff: Support telemedicine visits and assist subjects in AE reporting.
• CRO: Monitors telemedicine compliance and audits remote AE documentation.
• QA: Audits telemedicine and AE reporting systems for compliance.
• EC/IRB: Reviews and approves telemedicine procedures and AE reporting processes.

Accountability

The Principal Investigator is accountable for the conduct of telemedicine visits and AE reporting accuracy. The Sponsor is accountable for overall oversight and compliance with global regulations.

Procedure

1. Platform Validation
1.1 Use telemedicine platforms validated for security, privacy, and data retention.
1.2 Ensure compliance with HIPAA, GDPR, and FDA Part 11.
1.3 Document validation in Telemedicine Platform Log (Annexure-1).

2. Telemedicine Visits
2.1 Schedule visits according to protocol timelines.
2.2 Obtain subject consent for teleconsultation.
2.3 Conduct visits via secure video/audio systems.
2.4 Document visit details in Telemedicine Visit Log (Annexure-2).

3. Remote AE Identification
3.1 Instruct subjects to report AEs via phone, email, or telemedicine platform.
3.2 Investigators review and classify AE severity and causality.
3.3 Document in Remote AE Log (Annexure-3).

4. AE Documentation and Reporting
4.1 Record AE details in eCRF within 24 hours of identification.
4.2 Report SAEs to sponsor within regulatory timelines.
4.3 Maintain AE Notification Log (Annexure-4).

5. Data Privacy
5.1 Ensure encrypted communication and secure storage.
5.2 Maintain confidentiality per GDPR/HIPAA.
5.3 Document in Data Privacy Log (Annexure-5).

6. Training
6.1 Train investigators and staff in telemedicine workflows.
6.2 Provide subjects with instructions for reporting AEs remotely.
6.3 Record in Training Log (Annexure-6).

7. Inspection Readiness
7.1 Maintain inspection-ready telemedicine and AE reporting records.
7.2 Document mock inspections in Inspection Readiness Log (Annexure-7).

Abbreviations

• SOP: Standard Operating Procedure
• AE: Adverse Event
• SAE: Serious Adverse Event
• CRO: Contract Research Organization
• QA: Quality Assurance
• EC/IRB: Ethics Committee/Institutional Review Board
• GDPR: General Data Protection Regulation
• HIPAA: Health Insurance Portability and Accountability Act
• TMF: Trial Master File
• ISF: Investigator Site File
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization

Documents

1. Telemedicine Platform Log (Annexure-1)
2. Telemedicine Visit Log (Annexure-2)
3. Remote AE Log (Annexure-3)
4. AE Notification Log (Annexure-4)
5. Data Privacy Log (Annexure-5)
6. Training Log (Annexure-6)
7. Inspection Readiness Log (Annexure-7)

References

• FDA – Guidance on Remote Monitoring and Telemedicine
• EMA – Telemedicine in Clinical Trials
• CDSCO – Telemedicine Trial Rules
• ICH GCP – Adverse Event Reporting Standards
• WHO – Telemedicine and Remote AE Guidance

Version: 1.0

Approval Section

Annexures

Annexure-1: Telemedicine Platform Log

Annexure-2: Telemedicine Visit Log

Annexure-3: Remote AE Log

Annexure-4: AE Notification Log

Annexure-5: Data Privacy Log

Annexure-6: Training Log

Annexure-7: Inspection Readiness Log

Revision History

For more SOPs visit: Pharma SOP